Gene editing biotech Beam adds to drug delivery stable with $120M GuideTx buy

Not all gene editing treatments are created equal—that’s why Beam Therapeutics started out with multiple technologies from the likes of MIT, Harvard University, the Broad Institute and Editas Medicine. Now, it’s adding another arrow to its drug delivery quiver with its $120 million acquisition of GuideTx, a Georgia Tech spinout.